/ RecruitingNot Applicable 阿奇霉素颗粒在空腹及餐后条件下的人体生物等效性试验
[Translation] Bioequivalence study of azithromycin granules in humans under fasting and fed conditions
本研究考察空腹及餐后条件下湖北潜江制药股份有限公司生产的受试制剂阿奇霉素颗粒(规格:100mg/袋)与PLIVA公司持证的参比制剂阿奇霉素干混悬剂(商品名:Sumamed(舒美特),规格:100mg/5ml)单次口服的药动学特征,比较其相对生物利用度,评价两制剂间的生物等效性,为该试验制剂一致性评价提供依据。
次要研究目的
评价单次口服100mg/袋的受试制剂阿奇霉素颗粒或参比制剂(商品名:Sumamed(舒美特),规格:100mg/5ml)在健康受试者中的安全性。
[Translation] This study investigated the pharmacokinetic characteristics of the test preparation azithromycin granules (specification: 100 mg/bag) produced by Hubei Qianjiang Pharmaceutical Co., Ltd. and the reference preparation azithromycin dry suspension (trade name: Sumamed, specification: 100 mg/5 ml) certified by PLIVA under fasting and postprandial conditions, compared their relative bioavailability, evaluated the bioequivalence between the two preparations, and provided a basis for the consistency evaluation of the test preparation.
Secondary study objectives
To evaluate the safety of the test preparation azithromycin granules or the reference preparation (trade name: Sumamed, specification: 100 mg/5 ml) of a single oral dose of 100 mg/bag in healthy subjects.
100 Clinical Results associated with Hubei Qianjiang Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Hubei Qianjiang Pharmaceutical Co., Ltd.
100 Deals associated with Hubei Qianjiang Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Hubei Qianjiang Pharmaceutical Co., Ltd.